Company intelligence
CYTOO
About CYTOO
CYTOO is a preclinical stage drug discovery company specialized in muscular and neuromuscular disorders. CYTOO partners its versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates. CYOO has developed a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic). Core expertise lies on in vitro muscle regeneration, contraction, hypertrophy, and metabolism.
Verified activity
Signals from CYTOO
5 published signals
Research & Knowledge
CYTOO runs myotoxicity in the same system, on the same donors, with the same readouts, benchmarked against a reference myotoxicity compound library.
Reported by CYTOO
Research & Knowledge
CYTOO models the drivers of cachexia directly in primary human myotubes.
Reported by CYTOO
Research & Knowledge
CYTOO published findings from the REDEFINE 1 DXA substudy showing that 33.1% of weight lost on CagriSema was lean soft tissue versus 30.3% for semaglutide alone.
Reported by CYTOO
Research & Knowledge
CYTOO notes that Regeneron's COURAGE put semaglutide monotherapy near 34.5% and SURMOUNT-1 had tirzepatide closer to 25% in clinical trials.
Reported by CYTOO
Research & Knowledge
CYTOO notes that Apitegromab has shown it is feasible with 54.9% lean mass retention on top of tirzepatide in EMBRAZE.
Reported by CYTOO